Ortho Regenerative Technologies Announces Executive Leadership Changes
Philippe Deschamps appointed President and CEOFirst patient enrolment into the U.S. ORTHO-R Phase I / II clinical trial still imminent. MONTREAL, March 15, 2022 /PRNewswire/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) ("Ortho" or...